More possible exceptions to Tamoxifen treatment.
Please use seach re previously posted potential exceptions - high expression Cyclin D - possible gene types etc [A trial suggested there may even be a negative impact etc for high cyclin d expressors].
RB
ABSTRACT
http://www.medpagetoday.com/Hematolo...Cancer/tb/3314
MedPage Today Action Points
* Advise patients who ask that five years of adjuvant tamoxifen has been regarded as a standard of care for women whose breast tumors are estrogen-receptor positive, but that some women seem to be intrinsically resistant to the drug.
* Note that this study implies that such resistance is due to high levels of a protein whose job it is to activate estrogen receptors.
* Explain that these results raise the possibility that premenopausal breast cancer patients whose tumors overexpress Pak1 may need to be offered alternative endocrine treatment.
[ARTICLE at link gives details rb]
TECHNICAL
1: J Natl Cancer Inst. 2006 May 17;98(10):671-80. Related Articles, Links
Click here to read
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G.
Division of Pathology, Department of Laboratory Medicine, Lund University, Malmo, Sweden.
BACKGROUND: p21-activated kinase 1 (Pak1) phosphorylates many proteins in both normal and transformed cells. Its ability to phosphorylate and thereby activate the estrogen receptor alpha (ERalpha) potentially limits the effectiveness of antiestrogen treatment in breast cancer. Here we studied associations between Pak1 expression and subcellular localization in tumor cells and tamoxifen resistance. METHODS: Pak1 protein expression was evaluated in 403 primary breast tumors from premenopausal patients who had been randomly assigned to 2 years of adjuvant tamoxifen or no treatment. Tamoxifen response was evaluated by comparing recurrence-free survival in relation to Pak1 and ERalpha expression in untreated versus tamoxifen-treated patients. Tamoxifen responsiveness of human MCF-7 breast cancer cells that inducibly expressed constitutively active Pak1 or that transiently overexpressed wild-type Pak1 (Wt-Pak1) or Pak1 that lacked functional nuclear localization signals (Pak1DeltaNLS) was evaluated by analyzing cyclin D1 promoter activation and protein levels as markers for ERalpha activation. The response to tamoxifen in relation to Pak1 expression was analyzed in naturally tamoxifen-resistant Ishikawa human endometrial cancer cells. All statistical tests were two-sided. RESULTS: Among patients who had ERalpha-positive tumors with low Pak1 expression, those treated with tamoxifen had better recurrence-free survival than those who received no treatment (hazard ratio [HR] = 0.502, 95% confidence interval [CI] = 0.331 to 0.762; P = .001) whereas there was no difference in recurrence-free survival between treatment groups for patients whose tumors had high cytoplasmic (HR = 0.893, 95% CI = 0.420 to 1.901; P = .769) or any nuclear Pak1 expression (HR = 0.955, 95% CI = 0.405 to 2.250; P = .916). In MCF-7 cells, overexpression of Wt-Pak1, but not of Pak1DeltaNLS, compromised tamoxifen response by stimulating cyclin D1 expression. Treatment of Ishikawa cells with tamoxifen led to an increase in the amount of nuclear Pak1 and Pak1 kinase activity, suggesting that tamoxifen, to some extent, regulates Pak1 expression. CONCLUSIONS: Our data support a role for Pak1, particular Pak1 localized to the nucleus, in ERalpha signaling and in tamoxifen resistance.
PMID: 16705121 [PubMed - in process]
Threaded Mode